187 related articles for article (PubMed ID: 32146594)
21. Arsenic trioxide for the treatment of myelodysplastic syndromes.
Vey N
Expert Opin Pharmacother; 2004 Mar; 5(3):613-21. PubMed ID: 15013929
[TBL] [Abstract][Full Text] [Related]
22. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF
J Clin Oncol; 2006 Jun; 24(16):2456-64. PubMed ID: 16651647
[TBL] [Abstract][Full Text] [Related]
23. Realgar (α-As
Zhang M; Zhang JY; Sun MQ; Lu P; Liu JX
Chin J Integr Med; 2022 Mar; 28(3):281-288. PubMed ID: 32418175
[TBL] [Abstract][Full Text] [Related]
24. Karyotype and DNA-Methylation Responses in Myelodysplastic Syndromes following Treatment with Traditional Chinese Formula Containing Arsenic.
Shuzhen S; Rou M; Xiaomei H; Xiao-Hong Y; Yong-Gang X; Hongzhi W; Xiu-Peng Y
Evid Based Complement Alternat Med; 2012; 2012():969476. PubMed ID: 23118798
[TBL] [Abstract][Full Text] [Related]
25. Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome.
Roboz GJ; Ritchie EK; Curcio T; Samuel M; Provenzano J; Segovia J; Christos PJ; Mathew S; Allen-Bard S; Feldman EJ
Leuk Res; 2011 Apr; 35(4):522-5. PubMed ID: 20956016
[TBL] [Abstract][Full Text] [Related]
26. Acute lung injury induced by arsenic trioxide in a patient with refractory myelodysplastic syndrome.
Hassaballa HA; Lateef OB; Silver MR; Balk RA
J Crit Care; 2005 Mar; 20(1):111-3. PubMed ID: 16015525
[TBL] [Abstract][Full Text] [Related]
27. A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes.
Wei W; Zhou F; Zhang Y; Guo L; Shi H; Hou J
Leuk Res; 2012 Jun; 36(6):715-9. PubMed ID: 22277680
[TBL] [Abstract][Full Text] [Related]
28. Effects of Qinghuang Powder on Acute Myeloid Leukemia Based on Network Pharmacology, Molecular Docking, and In Vitro Experiments.
Zeng YJ; Wu M; Zhang H; Wu XP; Zhou L; Wan N; Wu ZH
Evid Based Complement Alternat Med; 2021; 2021():6195174. PubMed ID: 34992668
[TBL] [Abstract][Full Text] [Related]
29. A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
Sekeres MA; Maciejewski JP; Erba HP; Afable M; Englehaupt R; Sobecks R; Advani A; Seel S; Chan J; Kalaycio ME
Cancer; 2011 Mar; 117(6):1253-61. PubMed ID: 20960521
[TBL] [Abstract][Full Text] [Related]
30. [Apoptosis of in vitro cultured BMMNC from MDS patients induced by arsenic sulfide].
Yuan HJ; Xu RR; Ding RS; Jiang SH; Lu W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Apr; 14(2):276-80. PubMed ID: 16638196
[TBL] [Abstract][Full Text] [Related]
31. [Methylation of P15INK4B gene in patients with myelodysplastic syndromes and demethylating effects of drugs].
Ye XS; Liu T; Cui X; Meng WT; Xi YM
Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jan; 38(1):57-9. PubMed ID: 17294728
[TBL] [Abstract][Full Text] [Related]
32. Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients.
Zheng WL; Zhang GS; Xu YX; Shen JK; Dai CW; Pei MF
Leuk Res; 2008 Feb; 32(2):251-4. PubMed ID: 17920679
[TBL] [Abstract][Full Text] [Related]
33. Clinical Response to Traditional Chinese Herbs Containing Realgar (As
Zhou QB; Du Y; Zhang SS; Liu ZT; Ma R; Xu YG
Cancer Manag Res; 2021; 13():55-63. PubMed ID: 33442294
[TBL] [Abstract][Full Text] [Related]
34. Arsenic trioxide as a treatment for myelodysplastic syndrome.
Sekeres MA
Curr Hematol Malig Rep; 2006 Mar; 1(1):34-8. PubMed ID: 20425329
[TBL] [Abstract][Full Text] [Related]
35. Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study.
Galimberti S; Guerrini F; Salvi F; Petrini I; Gioia D; Messa E; Palumbo GA; Cilloni D; Petrini M; Levis A
J Hematol Oncol; 2012 Sep; 5():53. PubMed ID: 22964015
[TBL] [Abstract][Full Text] [Related]
36. Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.
List A; Beran M; DiPersio J; Slack J; Vey N; Rosenfeld CS; Greenberg P
Leukemia; 2003 Aug; 17(8):1499-507. PubMed ID: 12886236
[TBL] [Abstract][Full Text] [Related]
37. [Clinical application of professor MA Rou's experience in treating hematological disease by arsenic-containing Chinese herbal medicine].
Li L; Ma R
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 Aug; 31(8):1138-40. PubMed ID: 21910353
[TBL] [Abstract][Full Text] [Related]
38. Arsenic trioxide as a treatment for myelodysplastic syndrome.
Sekeres MA
Curr Hematol Rep; 2005 Jan; 4(1):59-63. PubMed ID: 15610661
[TBL] [Abstract][Full Text] [Related]
39. Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity.
Wu X; Hu Z; Nizzero S; Zhang G; Ramirez MR; Shi C; Zhou J; Ferrari M; Shen H
J Control Release; 2017 Dec; 268():92-101. PubMed ID: 29042320
[TBL] [Abstract][Full Text] [Related]
40. Decitabine shows synergistic effects with arsenic trioxide against myelodysplastic syndrome cells via endoplasmic reticulum stress-related apoptosis.
Huang L; Liu Z; Jiang H; Li L; Fu R
J Investig Med; 2019 Oct; 67(7):1067-1075. PubMed ID: 30898879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
